Direct-Acting Antiviral Agents for the Hepatitis C Virus-Infected Chronic Kidney Disease Population: The Dawn of a New Era

Juan Kusnir, David Roth

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

The introduction of direct-acting antiviral (DAA) agents with cure rates of >90% has changed the treatment of hepatitis C virus (HCV) in dramatic fashion. An extensive literature has documented the efficacy of these agents in the general population; however, patients with chronic kidney disease have been largely excluded from these trials. Recently published studies conducted in patients with chronic kidney disease are now demonstrating that the DAAs will also offer safe and effective therapy for the HCV-infected patient with CKD as well. As effective treatment protocols are offered to larger numbers of HCV-infected CKD patients, the decision regarding when is the most opportune time to treat, especially for the patient being considered for kidney transplantation will become of greater significance. Nephrologists will need to take a lead in these clinical decisions as obtaining a sustained viral response prior to transplant will effectively eliminate the patient as a candidate to receive a kidney from a hepatitis C virus-positive donor and the benefit of the shorter waiting times accompanying this strategy.

Original languageEnglish (US)
Pages (from-to)5-6
Number of pages2
JournalSeminars in Dialysis
Volume29
Issue number1
DOIs
StatePublished - Jan 1 2016

Fingerprint

Chronic Renal Insufficiency
Hepacivirus
Antiviral Agents
Population
Clinical Protocols
Kidney Transplantation
Tissue Donors
Transplants
Kidney
Therapeutics

ASJC Scopus subject areas

  • Nephrology

Cite this

Direct-Acting Antiviral Agents for the Hepatitis C Virus-Infected Chronic Kidney Disease Population : The Dawn of a New Era. / Kusnir, Juan; Roth, David.

In: Seminars in Dialysis, Vol. 29, No. 1, 01.01.2016, p. 5-6.

Research output: Contribution to journalArticle

@article{05c1c5243dab44d1b110cb49d01a630a,
title = "Direct-Acting Antiviral Agents for the Hepatitis C Virus-Infected Chronic Kidney Disease Population: The Dawn of a New Era",
abstract = "The introduction of direct-acting antiviral (DAA) agents with cure rates of >90{\%} has changed the treatment of hepatitis C virus (HCV) in dramatic fashion. An extensive literature has documented the efficacy of these agents in the general population; however, patients with chronic kidney disease have been largely excluded from these trials. Recently published studies conducted in patients with chronic kidney disease are now demonstrating that the DAAs will also offer safe and effective therapy for the HCV-infected patient with CKD as well. As effective treatment protocols are offered to larger numbers of HCV-infected CKD patients, the decision regarding when is the most opportune time to treat, especially for the patient being considered for kidney transplantation will become of greater significance. Nephrologists will need to take a lead in these clinical decisions as obtaining a sustained viral response prior to transplant will effectively eliminate the patient as a candidate to receive a kidney from a hepatitis C virus-positive donor and the benefit of the shorter waiting times accompanying this strategy.",
author = "Juan Kusnir and David Roth",
year = "2016",
month = "1",
day = "1",
doi = "10.1111/sdi.12456",
language = "English (US)",
volume = "29",
pages = "5--6",
journal = "Seminars in Dialysis",
issn = "0894-0959",
publisher = "Wiley-Blackwell",
number = "1",

}

TY - JOUR

T1 - Direct-Acting Antiviral Agents for the Hepatitis C Virus-Infected Chronic Kidney Disease Population

T2 - The Dawn of a New Era

AU - Kusnir, Juan

AU - Roth, David

PY - 2016/1/1

Y1 - 2016/1/1

N2 - The introduction of direct-acting antiviral (DAA) agents with cure rates of >90% has changed the treatment of hepatitis C virus (HCV) in dramatic fashion. An extensive literature has documented the efficacy of these agents in the general population; however, patients with chronic kidney disease have been largely excluded from these trials. Recently published studies conducted in patients with chronic kidney disease are now demonstrating that the DAAs will also offer safe and effective therapy for the HCV-infected patient with CKD as well. As effective treatment protocols are offered to larger numbers of HCV-infected CKD patients, the decision regarding when is the most opportune time to treat, especially for the patient being considered for kidney transplantation will become of greater significance. Nephrologists will need to take a lead in these clinical decisions as obtaining a sustained viral response prior to transplant will effectively eliminate the patient as a candidate to receive a kidney from a hepatitis C virus-positive donor and the benefit of the shorter waiting times accompanying this strategy.

AB - The introduction of direct-acting antiviral (DAA) agents with cure rates of >90% has changed the treatment of hepatitis C virus (HCV) in dramatic fashion. An extensive literature has documented the efficacy of these agents in the general population; however, patients with chronic kidney disease have been largely excluded from these trials. Recently published studies conducted in patients with chronic kidney disease are now demonstrating that the DAAs will also offer safe and effective therapy for the HCV-infected patient with CKD as well. As effective treatment protocols are offered to larger numbers of HCV-infected CKD patients, the decision regarding when is the most opportune time to treat, especially for the patient being considered for kidney transplantation will become of greater significance. Nephrologists will need to take a lead in these clinical decisions as obtaining a sustained viral response prior to transplant will effectively eliminate the patient as a candidate to receive a kidney from a hepatitis C virus-positive donor and the benefit of the shorter waiting times accompanying this strategy.

UR - http://www.scopus.com/inward/record.url?scp=85000471171&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85000471171&partnerID=8YFLogxK

U2 - 10.1111/sdi.12456

DO - 10.1111/sdi.12456

M3 - Article

C2 - 26781743

AN - SCOPUS:85000471171

VL - 29

SP - 5

EP - 6

JO - Seminars in Dialysis

JF - Seminars in Dialysis

SN - 0894-0959

IS - 1

ER -